A multicenter study on the clinical efficacy and mechanism of glucocorticoids against interferon-gamma self-syndrome in patients with interferon-gamma self-syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079820

Enrollment

Unknown

Registered

2024-01-12

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interventional study

Interventions

experimental group:Oral prednisone acetate

control group:Oral placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : ? patients diagnosed with anti-INF-? autoantibody syndrome ; ?the infection control was stable, with the following manifestations : a.the patient 's anti-INF-? autoantibody titer increased ( 1 : 2500 ) ; b. Immunoglobulin, erythrocyte sedimentation rate and other immune indicators increased or accompanied by skin, eye and other non-infectious damage. Patients with? and any one or more of the ? meet the inclusion criteria.

Exclusion criteria

Exclusion criteria: Exclusion criteria : ? HIV infection or AIDS patients ; ? Patients with contraindications to glucocorticoid therapy.

Design outcomes

Primary

Measure	Time frame
Anti-interferon-? autoantibody;	—

Secondary

Measure	Time frame
Acute exacerbation;Safety;	—

Countries

China

Contacts

Public ContactZhiyi He

The First Affiliated Hospital of Guangxi Medical University

zhiyi-he@163.com+86 187 7801 7698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026